Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Sibylle Loibl; Chiun Sheng Huang; Max S. Mano; Eleftherios P. Mamounas; Charles E. Geyer; Michael Untch; Jean Christophe Thery; Ingo Schwaner; Steven Limentani; Niklas Loman; Kristina Lübbe; Jenny C. Chang; Thomas Hatschek; David Tesarowski; Chunyan Song; Sanne Lysbet de Haas; Thomas Boulet; Chiara Lambertini; Norman Wolmark

doi:10.1038/s41523-022-00477-z

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Sibylle Loibl, Chiun Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

Original language	English (US)
Article number	106
Journal	npj Breast Cancer
Volume	8
Issue number	1
DOIs	https://doi.org/10.1038/s41523-022-00477-z
State	Published - Dec 2022

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

Divisions

Medical Oncology

Access to Document

10.1038/s41523-022-00477-z

Cite this

Loibl, S., Huang, C. S., Mano, M. S., Mamounas, E. P., Geyer, C. E., Untch, M., Thery, J. C., Schwaner, I., Limentani, S., Loman, N., Lübbe, K., Chang, J. C., Hatschek, T., Tesarowski, D., Song, C., Lysbet de Haas, S., Boulet, T., Lambertini, C., & Wolmark, N. (2022). Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. npj Breast Cancer, 8(1), Article 106. https://doi.org/10.1038/s41523-022-00477-z

Loibl, S, Huang, CS, Mano, MS, Mamounas, EP, Geyer, CE, Untch, M, Thery, JC, Schwaner, I, Limentani, S, Loman, N, Lübbe, K, Chang, JC, Hatschek, T, Tesarowski, D, Song, C, Lysbet de Haas, S, Boulet, T, Lambertini, C & Wolmark, N 2022, 'Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE', npj Breast Cancer, vol. 8, no. 1, 106. https://doi.org/10.1038/s41523-022-00477-z

@article{2ee67ce3cf79430f85e55611cb564e65,

title = "Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE",

abstract = "Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3\%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2\%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.",

author = "Sibylle Loibl and Huang, \{Chiun Sheng\} and Mano, \{Max S.\} and Mamounas, \{Eleftherios P.\} and Geyer, \{Charles E.\} and Michael Untch and Thery, \{Jean Christophe\} and Ingo Schwaner and Steven Limentani and Niklas Loman and Kristina L{\"u}bbe and Chang, \{Jenny C.\} and Thomas Hatschek and David Tesarowski and Chunyan Song and \{Lysbet de Haas\}, Sanne and Thomas Boulet and Chiara Lambertini and Norman Wolmark",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41523-022-00477-z",

language = "English (US)",

volume = "8",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

AU - Loibl, Sibylle

AU - Huang, Chiun Sheng

AU - Mano, Max S.

AU - Mamounas, Eleftherios P.

AU - Geyer, Charles E.

AU - Untch, Michael

AU - Thery, Jean Christophe

AU - Schwaner, Ingo

AU - Limentani, Steven

AU - Loman, Niklas

AU - Lübbe, Kristina

AU - Chang, Jenny C.

AU - Hatschek, Thomas

AU - Tesarowski, David

AU - Song, Chunyan

AU - Lysbet de Haas, Sanne

AU - Boulet, Thomas

AU - Lambertini, Chiara

AU - Wolmark, Norman

PY - 2022/12

Y1 - 2022/12

N2 - Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

AB - Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

UR - https://www.scopus.com/pages/publications/85138309735

UR - https://www.scopus.com/inward/citedby.url?scp=85138309735&partnerID=8YFLogxK

U2 - 10.1038/s41523-022-00477-z

DO - 10.1038/s41523-022-00477-z

M3 - Article

AN - SCOPUS:85138309735

SN - 2374-4677

VL - 8

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 106

ER -

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Abstract

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this